Chiesi’s Rare Disease Strategy Expands to Genetic Meds via Alliance With CRISPR Startup Arbor

Chiesi Global Rare Diseases is committing up to $115 million to begin a collaboration on Arbor Biotechnologies’ in vivo gene-editing therapy for primary hyperoxaluria type 1, an inherited liver disorder. It’s the rare disease company’s first foray into genetic medicines. The post Chiesi’s Rare Disease Strategy Expands to Genetic Meds via Alliance With CRISPR Startup…

Read More

Hospitals & Clinics Still Paid Unequally for Same Care, Research Shows

A new Trilliant Health report revealed wide disparities in provider payments, with academic medical centers and certain payer-affiliated clinics receiving far higher reimbursements than their peers for the same services. The findings emphasize just how much opaque pricing practices continue to drive inequities in the U.S. healthcare system. The post Hospitals & Clinics Still Paid…

Read More